Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Vertex Pharmaceuticals Incorporated. A complete text table follows the diagram.
Cystic-fibrosis medicines still generate 98% of product revenue, but a fast therapy transition and the first CASGEVY and JOURNAVX sales are reshaping the mix
Swipe to explore
Other CF combines the directly reported KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI category. Other operating costs combines $0.5M acquired IPR&D and $0.2M contingent-consideration expense.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| TRIKAFTA / KAFTRIO | 1 | $2.4B | 78.8% of product revenue |
| ALYFTREK | 1 | $424M | Nearly 8x year-over-year growth |
| Other CF medicines | 1 | $136M | Legacy cystic-fibrosis portfolio |
| CASGEVY | 1 | $42.9M | Gene-editing therapy |
| JOURNAVX | 1 | $29M | Non-opioid pain medicine |
| Product revenue | 2 | $3.0B | 8% year-over-year growth |
| Operating income | 3 | $1.1B | 38.1% operating margin |
| Cost of sales | 3 | $393M | 13.2% of product revenue |
| Research & development | 3 | $962M | Pipeline and development engine |
| Selling, general & administrative | 3 | $494M | Commercial launch investment |
| Other operating costs | 3 | $0.7 | Acquired IPR&D and contingent consideration |
| Net interest income | 3 | $115M | Return on $13.0B cash portfolio |
| Income before tax | 4 | $1.3B | 42.0% of revenue |
| Net income | 5 | $1.0B | $4.02 diluted EPS |
| Income tax | 5 | $222M | 17.7% effective rate |
| From | To | Value |
|---|---|---|
| TRIKAFTA / KAFTRIO | Product revenue | $2.4B |
| ALYFTREK | Product revenue | $424M |
| Other CF medicines | Product revenue | $136M |
| CASGEVY | Product revenue | $42.9M |
| JOURNAVX | Product revenue | $29M |
| Product revenue | Operating income | $1.1B |
| Product revenue | Cost of sales | $393M |
| Product revenue | Research & development | $962M |
| Product revenue | Selling, general & administrative | $494M |
| Product revenue | Other operating costs | $0.7 |
| Operating income | Income before tax | $1.1B |
| Net interest income | Income before tax | $115M |
| Income before tax | Net income | $1.0B |
| Income before tax | Income tax | $222M |